You can buy or sell Hemispherx and other stocks, options, ETFs, and crypto commission-free!
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. Read More The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
52 Week High
52 Week Low
Seeking AlphaMar 13
Hemispherx Bio up 8% on Ampligen progress
Nano cap Hemispherx Biopharma (HEB +7.5% ) is up on more than triple normal volume following its update on its Ampligen programs.
Yahoo FinanceMar 13
Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs
Hemispherx Provides Quarterly Summary of Rapidly Advancing Oncology Clinical Programs OCALA, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on unmet medical needs in immunology, announced today the first of a series of planned quarterly press release updates highlighting the progress and achievement of milestones in the Company’s ongoing clinical trials evaluating Ampligen’s ability to reprogram t...
Yahoo FinanceMar 6
Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
OCALA, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that the Company’s previously announced rights offering (the “Rights Offering”) expired on Tuesday, March 5, 2019 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering...
Expected Mar 29, After Hours